• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    RadNet (RDNT) Lifted Guidance, Is The Stock Still Trading At A Discount?

    Simply Wall St·11/10/2026 08:22:13
    Listen to the news

    RadNet (RDNT) is back in focus after reporting record third quarter 2026 revenue and Adjusted EBITDA, raising its full year guidance, and announcing a pending acquisition of teleradiology provider ONRAD.

    RadNet’s recent earnings beat and guidance upgrade have arrived alongside a 10.5% 30-day share price return and a 10.5% year-to-date share price gain. The 3-year total shareholder return of 172.1% contrasts with a 1-year total shareholder return that is slightly in decline, suggesting long-term momentum with some shorter-term cooling in investor enthusiasm around the stock.

    Scan RadNet alongside other companies riding similar momentum in medical imaging and healthcare AI by reviewing the hand picked 36 healthcare AI stocks that meet strict fundamental criteria.

    RadNet has already rewarded long term holders, yet the latest surge after record Q3 numbers raises a sharper question. Is this where most of the upside is already in the rear view mirror, or is valuation still leaving meaningful runway?

    Most Popular Narrative: 17% Undervalued

    RadNet closed at $78.38, while the analyst consensus Narrative on Simply Wall St anchors fair value at $94.63 and ties that gap directly to measured progress in AI driven imaging and software.

    The key requirement is that RadNet converts its heavy AI and digital health investment, including acquisitions and joint ventures with health systems, into sustainably higher margins and free cash flow despite ongoing labor and capital cost pressures.

    The current valuation analysis suggests that the share price does not fully reflect the company’s record Q2 2026 revenue and adjusted EBITDA, growing advanced imaging contribution and rapidly scaling DeepHealth ARR. This narrative views that combination as consistent with RadNet being undervalued and the stock setup being favorable.

    See why 9 investors see RadNet as 17% undervalued.

    Result: Fair Value of $94.63 (UNDERVALUED)

    Still, the RadNet narrative can break if heavy AI and digital health spending keeps compressing free cash flow, or if new imaging capacity ends up underused.

    Find out about the key risks to this RadNet narrative.

    Next Steps

    Feeling the bullish tone around RadNet but unsure whether it fits your own approach and risk tolerance? Pressure test the optimism and see where you land by reviewing its 3 key rewards.

    Looking for more investment ideas beyond RadNet?

    Do not stop your research with a single stock. Broaden your watchlist with focused screens that surface different types of opportunities across quality, valuation, and resilience.